Literature DB >> 11260864

Multiple genetic alterations involved in the tumorigenesis of human cholangiocarcinoma: a molecular genetic and clinicopathological study.

W M Cong1, A Bakker, P A Swalsky, S Raja, J Woods, S Thomas, A J Demetris, S D Finkelstein.   

Abstract

PURPOSE: Cholangiocarcinoma (CC) is the second most common malignant tumor in the liver and the molecular genetic alterations involved in the tumorigenesis of CC have not been well studied. PATIENTS AND METHODS: The authors analyzed the loss of heterozygosity (LOH) in four tumor suppressor genes, including the adenomatous polyposis coli (APC) gene, the deleted in colon cancer (DCC) gene, the 8-hydroguanine-specific DNA glycosylase (OGG1) gene, and the p53 gene in 22 surgically resected primary CCs by using microdissection-based PCR amplification and direct DNA sequencing.
RESULTS: A total of 19 (86.4%) out of 22 CCs exhibited genetic alterations, of which 11 (57.9%) and eight (42.1%) cases showed one and more than one gene alterations, respectively. The frequency of genetic alterations of the four genes studied ranged in order from high to low as APC (68.8%) > DCC (46.2%) > OGG1 (41.7%) > p53 (37.5%). Based on the pattern of altered genes and their correlation with clinical and pathological parameters, the genetic alterations were classified into three groups: group I: no detectable genetic alterations (n = 3, 13.6%); group II: LOH in APC and/or DCC (n = 9, 40.9%); and group III: LOH in OGG1 and/or p53 occurred separately or combined with LOH in APC and/or DCC (n = 10, 45.5%). The > or = 3-year survival rates between group II and group III are 88.9% and 30%, respectively (P < 0.05). No significant differences were found between genetic alterations and tumor size, tumor type, tumor invasion, TNM staging, and tumor differentiation (P > 0.05).
CONCLUSION: Accumulation of multiple genetic alterations are involved in the tumorigenesis of CC, of which genetic alterations of APC and DCC occur at a relatively early stage, and of OGG1 and p53 occur at a relatively late stage during development of CC.

Entities:  

Mesh:

Year:  2001        PMID: 11260864     DOI: 10.1007/s004320000194

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  8 in total

1.  Distinguishing de novo second cancer formation from tumor recurrence: mutational fingerprinting by microdissection genotyping.

Authors:  R Rolston; E Sasatomi; J Hunt; P A Swalsky; S D Finkelstein
Journal:  J Mol Diagn       Date:  2001-11       Impact factor: 5.568

2.  Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma.

Authors:  David T Tse
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 3.  The significance of genetics for cholangiocarcinoma development.

Authors:  Luca Maroni; Irene Pierantonelli; Jesus M Banales; Antonio Benedetti; Marco Marzioni
Journal:  Ann Transl Med       Date:  2013-10

4.  Mutation analysis of APC gene in gastric cancer with microsatellite instability.

Authors:  Dian-Chun Fang; Yuan-Hui Luo; Shi-Ming Yang; Xiao-An Li; Xian-Long Ling; Li Fang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

5.  Prognostic significance of microsatellite alterations at 1p36 in cholangiocarcinoma.

Authors:  Temduang Limpaiboon; Sumonta Tapdara; Patcharee Jearanaikoon; Banchob Sripa; Vajarabhongsa Bhudhisawasdi
Journal:  World J Gastroenterol       Date:  2006-07-21       Impact factor: 5.742

Review 6.  p53 status and its prognostic role in extrahepatic bile duct cancer: a meta-analysis of published studies.

Authors:  Juan Wang; Xuefeng Wang; Shuyang Xie; Zhonghai Yan; Zunling Li; Youjie Li; Lei Wang; Fei Jiao
Journal:  Dig Dis Sci       Date:  2010-07-29       Impact factor: 3.199

7.  Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations.

Authors:  Young-Ho Kim; Eun-Kyung Hong; Sun-Young Kong; Sung-Sik Han; Seoung-Hoon Kim; Je-Keun Rhee; Soo-Kyung Hwang; Sang-Jae Park; Tae-Min Kim
Journal:  Oncotarget       Date:  2016-04-26

Review 8.  Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma.

Authors:  Hector Perez-Montoyo
Journal:  Cells       Date:  2020-03-04       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.